Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Saved in:
| Title: | Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. |
|---|---|
| Authors: | Brunner AM; Massachusetts General Hospital, Boston, Massachusetts, USA., Esteve J; Hospital Clínic, Barcelona, Spain., Porkka K; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Knapper S; School of Medicine, Cardiff University, Cardiff, UK., Traer E; Oregon Health & Science University, Portland, Oregon, USA., Scholl S; University Hospital Jena, Jena, Germany., Garcia-Manero G; MD Anderson Cancer Center, Houston, Texas, USA., Vey N; Institut Paoli-Calmettes, Marseille, France., Wermke M; TU Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany., Janssen JJWM; Amsterdam University Medical Centers, Amsterdam, The Netherlands., Narayan R; Massachusetts General Hospital, Boston, Massachusetts, USA., Fleming S; The Alfred Hospital, Melbourne, Victoria, Australia., Loo S; The Alfred Hospital, Melbourne, Victoria, Australia., Tovar N; Hospital Clínic, Barcelona, Spain., Kontro M; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Ottmann OG; School of Medicine, Cardiff University, Cardiff, UK., Naidu P; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Sun H; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Han M; Cure Ventures, Boston, Massachusetts, USA., White R; Novartis Ireland Limited, Dublin, Ireland., Zhang N; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Mohammed A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Sabatos-Peyton CA; Larkspur Biosciences, Cambridge, Massachusetts, USA., Steensma DP; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA., Rinne ML; Blueprint Medicines, Cambridge, Massachusetts, USA., Borate UM; Oregon Health & Science University, Portland, Oregon, USA., Wei AH; The Peter MacCallum Cancer Centre and Royal Melbourne Hospital Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia. |
| Source: | American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. E32-E36. Date of Electronic Publication: 2023 Nov 22. |
| Publication Type: | Clinical Trial, Phase I; Letter; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1096-8652 |
|---|---|
| DOI: | 10.1002/ajh.27161 |
